NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

Part of paid clinical trials in Houston, Texas.

Sponsor
Baylor College of Medicine
Study ID
NCT07211737
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
1 Year - 24 Years
Healthy Volunteers
Not accepted

Interventions

  • i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells — GENETIC
    Dose Level 1: 3 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7/m\^2 of C7R.GD2.CAR T cells given 5 days later.
  • i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells — GENETIC
    Dose Level 2: 6 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7 cells/m\^2 of C7R.GD2.CAR T cells given 5 days later.
  • i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells — GENETIC
    Dose Level 3: 12 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7 cells/m\^2 of C7R.GD2.CAR T cells given 5 days later.

Study Details

The purpose of this study is to find the largest safe dose of i15.NKG2D.zeta-NK cells in combination with C7R.GD2.CAR-T cells, and additionally to evaluate how long they can be detected in patients' blood and what affect they have on patients' cancer. Patients eligible for this study have neuroblastoma or osteosarcoma that expresses a substance on the cancer cells called GD2. This cancer has either come back after treatment or did not respond to the standard or other investigational treatments or therapies used to treat it. There is no standard treatment for these types of advanced cancers at this time. This is a gene transfer research study using special immune cells called NK cells and T cells. NK cells and T cells are types of white blood cell that help the body fight infection. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: NK cells and T cells. T cells are special infection-fighting blood cells that can kill cells infected with viruses and tumor cells. NK cells, another kind of infection-fighting cell, can recognize a wide range of cells in distress, including tumor cells and cells that help protect tumor cells in the cancer environment. Both NK cells and T cells have been used individually to treat patients with cancers. They have shown promise, but have not been strong enough individually to cure most patients. Investigators have found from previous research that we can put a new gene into T cells that will make them recognize GD2, a substance found on almost all neuroblastoma and osteosarcoma cells. We can also put a new gene into NK cells that help them fight the tumor environment. Investigators know that T cells and NK cells need substances called cytokines to survive but the cells do not get enough cytokines after infusion into the body; therefore, the investigators have added the genes C7R and IL15 into the T and NK cells, respectively, to give each cell a constant supply of cytokine that helps them to survive longer. The C7R.GD2.CAR-T cells and i15.NKG2D.zeta-NK cells are investigational products not approved by the Food and Drug Administration.

Key Dates

Start date
May 31, 2026
Status verified
Feb 2026
Primary completion
Apr 30, 2029
Completion
Apr 30, 2044

Study Design

Enrollment
27 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells
    Three dose levels will be evaluated. This is a dose escalating trial which will infuse doses of i15.NKG2D.zeta NK cells followed by a fixed dose of C7R.GD2.CAR T cells 5 days later.

Primary Outcome Measure

Dose-limiting toxicity (DLT) rate [ Time Frame: 4 weeks post-CAR-T cell infusion ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Texas Children's HospitalHoustonTexas77030
Robin Parihar, MD
[email protected]
832-824-4746

Find similar trials in Houston, TX

By condition
Neuroblastoma
By specialty
OncologyPediatric oncology
By research site
Texas Children's Hospital· Houston, TX

Related Studies